Relationship of serum nesfatin-1 levels with body mass index and c-reactive protein in patients presenting to the emergency department with epileptic seizures
Postgraduate Medicine, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.1080/00325481.2026.2696625
- Dergi Adı: Postgraduate Medicine
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EBSCO Education Source, Educational research abstracts (ERA), EMBASE, MEDLINE, Education Source Ultimate (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Anahtar Kelimeler: Epilepsy, nesfatin-1, emergency department, inflammation, biomarker
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction: Reliable biomarkers reflecting acute seizure activity in patients presenting to the emergency department remain insufficiently defined. This study aimed to compare serum nesfatin-1 levels in patients presenting with epileptic seizures and healthy controls, and to evaluate their associations with clinical, demographic, and inflammatory parameters. Methods: This cross-sectional study included 216 participants, comprising 131 patients admitted to the emergency department due to epileptic seizures and 85 age- and sex-matched healthy controls. Demographic characteristics, comorbidities, antiseizure medication use, seizure features, and laboratory parameters were recorded. Serum nesfatin-1 concentrations were measured using enzyme-linked immunosorbent assay (ELISA). Group comparisons were performed using the Mann-Whitney U test, and correlations were analyzed with Spearman’s correlation coefficient. Results: Serum nesfatin-1 levels were significantly higher in patients with epileptic seizures compared with controls (p < 0.001). C-reactive protein (CRP) levels were also elevated in the patient group (p < 0.05). Nesfatin-1 concentrations showed positive correlations with age, CRP levels, and seizure duration, and negative correlations with height and body weight (all p < 0.05). Additionally, sex, diabetes mellitus, congestive heart failure, and type of antiseizure medication were significantly associated with circulating nesfatin-1 levels. Conclusion: Serum nesfatin-1 levels are elevated in patients presenting with epileptic seizures and are associated with inflammatory markers, seizure duration, and metabolic parameters. These findings suggest that nesfatin-1 may reflect integrated neuroinflammatory and metabolic responses occurring during acute seizure episodes. Further prospective studies are required to determine its clinical utility and prognostic value.